|
| 36287227 | Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. | Blood Adv | 2023 |
| 37885824 | Cross-Study Replicability in Cluster Analysis. | Stat Sci | 2023 |
| 37146250 | Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. | Blood | 2023 |
| 37407670 | A harmonized resource of integrated prostate cancer clinical, -omic, and signature features. | Sci Data | 2023 |
| 36717653 | A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. | Leukemia | 2023 |
| 36511902 | The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. | Mol Cancer Res | 2023 |
| 36711769 | curatedPCaData: Integration of clinical, genomic, and signature features in a curated and harmonized prostate cancer data resource. | bioRxiv | 2023 |
| 36732326 | Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors. | Blood Cancer J | 2023 |
| 36315919 | Rare Germline <i>ATM</i> Variants Influence the Development of Chronic Lymphocytic Leukemia. | J Clin Oncol | 2023 |
| 34743191 | A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. | Leukemia | 2022 |
| 35737367 | Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. | JAMA Oncol | 2022 |
| 36125434 | Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? | Cancer Prev Res (Phila) | 2022 |
| 35172272 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. | Eur J Cancer | 2022 |
| 35170759 | Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. | Br J Haematol | 2022 |
| 34788401 | Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. | Blood | 2022 |
| 32820271 | A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. | Leukemia | 2021 |
| 33684943 | Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. | Blood | 2021 |
| 33500320 | Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34939926 | Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. | Elife | 2021 |
| 34534514 | Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. | Lancet Oncol | 2021 |
| 34311724 | Transcriptional landscape of PTEN loss in primary prostate cancer. | BMC Cancer | 2021 |
| 33373063 | Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. | Am J Hematol | 2021 |
| 33168599 | Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. | Mol Cancer Res | 2021 |
| 31157686 | A New Classification of Benign, Premalignant, and Malignant Endometrial Tissues Using Machine Learning Applied to 1413 Candidate Variables. | Int J Gynecol Pathol | 2020 |
| 32913135 | Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. | Clin Cancer Res | 2020 |
| 33015524 | Systematic Assessment of Tumor Purity and Its Clinical Implications. | JCO Precis Oncol | 2020 |
| 30333152 | Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. | Mol Cancer Res | 2019 |
| 37736115 | Modeling genetic heterogeneity of drug response and resistance in cancer. | Curr Opin Syst Biol | 2019 |
| 31208944 | Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. | Lancet Haematol | 2019 |
| 30578319 | Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. | Proc Natl Acad Sci U S A | 2019 |
| 30602500 | Low Expression of the Androgen-Induced Tumor Suppressor Gene <i>PLZF</i> and Lethal Prostate Cancer. | Cancer Epidemiol Biomarkers Prev | 2019 |
| 29141848 | MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. | Cancer Epidemiol Biomarkers Prev | 2018 |
| 30469014 | Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration. | iScience | 2018 |
| 28074002 | Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues. | Mol Cancer Res | 2017 |
| 28700821 | Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. | Cancer | 2017 |
| 28871082 | Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. | Nat Commun | 2017 |
| 27663590 | Prognostic Utility of a New mRNA Expression Signature of Gleason Score. | Clin Cancer Res | 2017 |
| 27078000 | Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer. | PLoS Comput Biol | 2016 |
| 26490316 | Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. | Clin Cancer Res | 2016 |
| 27980733 | The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. | Cancer Metab | 2016 |
| 27325648 | Cholesterol Metabolism and Prostate Cancer Lethality. | Cancer Res | 2016 |
| 25371445 | Association of prostate cancer risk variants with gene expression in normal and tumor tissue. | Cancer Epidemiol Biomarkers Prev | 2015 |
| 25870172 | Molecular differences in transition zone and peripheral zone prostate tumors. | Carcinogenesis | 2015 |
| 25937617 | Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. | J Mol Diagn | 2015 |
| 24497570 | A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. | EMBO Mol Med | 2014 |
| 24700801 | Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. | J Natl Cancer Inst | 2014 |
| 24418822 | De novo fatty acid synthesis at the mitotic exit is required to complete cellular division. | Cell Cycle | 2014 |
| 23374354 | Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. | Cell | 2013 |
| 24240475 | A network of epigenetic regulators guides developmental haematopoiesis in vivo. | Nat Cell Biol | 2013 |
| 23550061 | curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. | Database (Oxford) | 2013 |